Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Supernus ...

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of ...

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

Morning. Today, we discuss how Duchenne patients and their families are responding to the shelving of Sarepta Therapeutics’ ...

KRd as a potential standard-of-care regimen in this hard-to-treat population of high-risk, newly diagnosed multiple myeloma,” said Lisa B. Leypoldt, MD.

To get an above-average dividend yield (compared to the S&P 500) while minimizing the risks that come with investing in ...

The global Healthcare Analytical Testing Services Market, valued at US$6.33 billion in 2024 stood at US$7.48 billion in 2025 and is ...